Aspect Imaging

About Aspect Imaging

Aspect Imaging operates as a developer and manufacturer of compact magnetic resonance imaging (MRI) and nuclear magnetic resonance (NMR) systems. Founded in 2007 by Uri Rapoport, the Israeli company focuses on making MRI technology more affordable, accessible, and easier to use than conventional high-field systems. Rapoport, who also serves as the company's CEO, aimed to simplify complex imaging technology for both medical and industrial applications.

The company's core innovation is its permanent magnet technology, which eliminates the need for cryogens, specialized shielded rooms, and complex maintenance associated with traditional superconducting MRI machines. This design allows for a smaller footprint, lower operating costs, and the ability to place the systems at the point-of-care, such as in neonatal intensive care units (NICUs) and emergency rooms. Aspect Imaging has secured significant funding, accumulating a total of $150 million over several rounds to support the development and commercialization of its products.

Aspect Imaging's business is structured into three primary units: clinical MRI, preclinical MRI, and advanced industrial solutions. The company generates revenue through the sale of these specialized imaging systems to hospitals, clinics, research institutions, and industrial clients. In the clinical market, key products include the Embrace® Neonatal MRI system, the first of its kind to be cleared by the FDA for use directly within the NICU, and the WristView™ system for dedicated hand and wrist imaging. The preclinical division offers the M-Series line of compact MRI systems (M3, M5, M7) for small animal imaging, serving researchers in fields like oncology, neuroscience, and cardiology. These systems feature user-friendly software that doesn't require operators to have extensive knowledge of MR physics. For industrial markets, Aspect provides solutions like the FlowScan for real-time rheological analysis of materials such as drilling mud and food products.

The primary benefit of Aspect's product portfolio is the democratization of MRI technology. By creating systems that are self-shielded, portable, and require minimal infrastructure, the company enables a wider range of facilities to adopt advanced imaging. For example, the Embrace® Neonatal system reduces the risks associated with transporting critically ill infants to different hospital departments for scans. The preclinical M-Series allows researchers to easily integrate high-quality 3D imaging into their laboratory workflows to monitor disease progression and assess therapeutic responses without the significant cost and complexity of conventional MRI.